Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,303.60
(
0.95%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
100.27
(
-0.92%
)
Bitcoin
78,200.55
(
-0.10%
)
News Focus
News Focus
Post# of 517558
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Investor2014

Send PM Follow Ignore
Followers 65
Posts 27752
Boards Moderated 0
Alias Born 11/23/2016

Investor2014

Re: falconer66a post# 347449

Monday, 01/31/2022 11:43:58 AM

Monday, January 31, 2022 11:43:58 AM

Post# of 517558

Shall we quibble over dosages, or efficacies?


Imo it is far too early to pontificate and/or quibble based on one pre-clinical murine paper on A3-71 so far out into the future, while the focus needs to be on getting revenue from A2-73.

I do feel uneasy, based on experience, when I see a biotech taking on lots of funding and starting on a new pipeline drug just before an important readout.

Hoping that the AVATAR readout is absolutely great and then in due course to dive into and pontificate deeper on A3-71 with much more excitement.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News